MedTrace Logo

R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL

NCT01148446 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2010-06-22

No results posted yet for this study

Summary

The study has the purpose to compare R-CHOP versus R-mini-CEOP in elderly patients (\>65 years) with Diffuse Large B Cell Lymphoma (DLBCL).

Conditions

  • Elderly Patients (>65 Years)
  • Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

DRUG

Cyclophosphamide

750 mg/mq IV, day 1

DRUG

Cyclophosphamide

50 mg/mq IV, day 1

DRUG

Doxorubicin

50 mg/mq IV, day1

DRUG

Vincristine

1,4 mg/mq (max 2 mg)IV, day 1

DRUG

Prednisone

75 mg/mq IV, days 1-5

DRUG

Prednisone

60 mg/mq IV/PO, days 1-5

DRUG

Epirubicin

50 mg/mq IV, day 1

DRUG

Vinblastine

5 mg/mq IV, day 1

DRUG

Rituximab

375 mg/mq IV, day 1

DRUG

G-CSF

300 µg tot., SC; days 7-11

Sponsors & Collaborators

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Francesco Merli, MD · U.O.A. di Ematologia Azienda Ospedale S. Maria Nuova

  • Marilena Bertini, MD · U.O.A. di Ematologia Ospedale Molinette

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
66 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2006-01-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01148446 on ClinicalTrials.gov